Document:

Exhibit 10.1

                          AGREEMENT AND PLAN OF MERGER

     This Agreement and Plan of Merger is made as of March 15, 2010, by and
between Genesis Biopharma, Inc., a Nevada corporation (the "Merging
Corporation"), and Freight Management Corp., a Nevada corporation (the
"Surviving Corporation"). (The corporations together are sometimes referred to
below as the "Constituent Corporations.")

     The Constituent Corporations agree as follows:

     1. The Merging Corporation is duly organized, existing, and in good
standing under the laws of the State of Nevada. It has one thousand (1,000)
shares of authorized capital stock, all of which are issued and outstanding.

     2. The Surviving Corporation is duly organized, validly existing, and
in good standing under the laws of the State of Nevada. It has one billion eight
hundred million (1,800,000,000) shares of authorized capital stock, all of which
are designated as common stock. One hundred twenty-one million four hundred
forty thousand (121,440,000) shares of common stock are issued and outstanding
(taking into effect a 24-for-1 forward stock split effectuated by the Surviving
Corporation on March 15, 2010, which post-split shares are subject to a
mandatory exchange by the Surviving Corporation's stockholders of stock
certificates issued prior to the stock split ).

     3. The Boards of Directors of the Constituent Corporations deem it in
the best interests of the corporations and their stockholders that the Merging
Corporation be merged with and into Surviving Corporation in accordance with
Nevada Revised Statutes Chapter 92A. The Boards hereby adopt on behalf of their
corporations the plan of reorganization set forth in this Agreement and Plan of
Merger.

     4. Merger. The Merging Corporation shall be merged with and into the
Surviving Corporation, which shall survive the merger. The Merging Corporation's
separate existence shall cease on the effective date of the merger, which shall
be the later of March 15, 2010, or the date on which the Articles of Merger are
accepted for filing by the Office of the Secretary of State of the State of
Nevada. Without any other transfer or documentation, on the effective date of
the merger, the Surviving Corporation shall (i) succeed to all of the Merging
Corporation's rights and property; and (ii) be subject to all the Merging
Corporation's liabilities and obligations.

     Notwithstanding the above, after the effective date of the merger, the
Surviving Corporation's proper officers and directors may perform any acts
necessary or desirable to vest or confirm the Surviving Corporation's possession
of and title to any property or rights of the Merging Corporation, or otherwise
carry out this Agreement's purposes. This includes execution and delivery of
deeds, assurances, assignments, or other instruments.

     5. Conversion of Shares. By virtue of the merger and without any action
by any stockholder, upon the effective time of the merger, all of the shares of
the Merging Corporation will be converted into and will become that number of
fully paid and nonassessable shares of the Surviving Corporation's common stock
<PAGE>
and thereafter retired and cancelled. No fractional shares of the Surviving
Corporation shall be issued.

     The shares of Surviving Corporation outstanding immediately prior to
the merger shall not be changed by reason of the merger.

     6. Change in Articles of Incorporation and Bylaws: The Surviving
Corporation's Articles of Incorporation in effect on the effective date shall
continue to be its Articles of Incorporation, except that Article First thereof
shall be amended in its entirety to read as follows:

     "The name of the corporation is: Genesis Biopharma, Inc."

     The Surviving Corporation's Bylaws as in effect on the effective date
of the merger shall continue to be its Bylaws without change as a result of the
merger.

     7. Officers and Directors: The Merging Corporation's officers
immediately prior to the effective date of the merger shall become the officers
of the Surviving Corporation effective upon the merger and replace such officers
of the Surviving Corporation, until their successors have been duly elected or
appointed and qualified; such that, as of the effective date of the merger, the
Surviving Corporation's officers shall be as follows:

     Robert Brooke -- President and Chief Executive Officer

     Richard McKilligan -- Treasurer, Secretary, and Chief Financial Officer

     The Surviving Corporation's directors shall continue and remain as such
after the effective date of the merger for the full unexpired terms of their
respective offices, or until their successors have been duly elected or
appointed and qualified, subject to the resignations and appointments thereof.

     8. Abandonment of Merger: Any time prior to the effective date, this
merger may be abandoned without further obligation or liability by action of the
board of directors of either of the Constituent Corporations.

     9. Counterparts: This Agreement and Plan of Merger may be executed in
any number of counterparts, each of which shall constitute an original
instrument.

                            [Signature Page Follows]
<PAGE>
     IN WITNESS WHEREOF, the parties hereto have executed this Agreement and
Plan of Merger by their respective duly authorized officers, as of the date
first written above.

                             FREIGHT MANAGEMENT CORP.
                             (to be renamed Genesis Biopharma, Inc.)
                             "Surviving Corporation"

                             By: /s/ Ibrahim Abotaleb
                                 -----------------------------------------------
                                 Ibrahim Abotaleb, President and Chief Executive
                                 Officer

                             GENESIS BIOPHARMA, INC.
                             "Merging Corporation"

                             By: /s/ Robert Brooke
                                 -----------------------------------------------
                                 Robert Brooke, President and Chief Executive
                                 OfficerExhibit 10.2

                            ASSET PURCHASE AGREEMENT

     THIS ASSET PURCHASE  AGREEMENT is made this 15th day of March, 2010, by and
among Freight Management Corporation,  a Nevada corporation ("Parent"),  Genesis
Biopharma, Inc. ("Buyer"), a Nevada corporation and a wholly owned subsidiary of
Parent;  Hamilton  Atlantic,  a company  organized  under the laws of the Cayman
Islands ("Seller");  Pro-Fund Administration Ltd., a company organized under the
laws of Cypress;  Bristol  Investment Fund, Ltd., a company  organized under the
laws of the Cayman Islands;  Batavia Holdings Limited, a company incorporated in
Hong Kong;  and 0796625 B.C.  LTD., a company  incorporated  in Canada (each,  a
"Shareholder," and collectively, "Shareholders").

     The parties hereto desire to effect the purchase by Buyer of certain of the
assets of Seller relating to the development and  commercialization of anti-CD55
antibodies (the  "Anti-CD55  Antibody  Program"),  upon the terms and conditions
hereinafter set forth.

     To induce Buyer to enter into and perform this Agreement, Shareholders, who
as the  owners of all the  outstanding  shares of capital  stock of Seller  will
derive substantial  benefit from this Agreement,  desire to guarantee and become
liable for the  performance of all the  obligations  of Seller  pursuant to this
Agreement.

     Concurrent  with  the  closing  of the  transactions  contemplated  by this
Agreement,  Parent will enter into a Patent and Know How License  Agreement with
Cancer Research  Technology  Limited,  a company registered in England and Wales
("CRT"),  pursuant to which CRT will license to Buyer certain other intellectual
property related to the development and therapeutic use of anti-CD55 antibodies.

     NOW,  THEREFORE,  in  consideration  of the  premises  and  of  the  mutual
covenants hereinafter set forth, the parties hereto agree as follows:

     1. Sale and Purchase.

          (a) Assets and Properties to be Sold and Purchased. At the Closing (as
herein defined), Seller shall sell and Buyer shall purchase,  subject to all the
terms and conditions of this Agreement,  the following  assets and properties of
Seller (collectively, the "Purchased Assets"):

               (i) Patents  and Patent  Applications.  All of Seller's  patents,
patent   rights,   patent   applications,    including   reissues,   extensions,
substitutions,  continuations, divisions, continuation-in-part applications, and
supplementary protection certificates in any part of the world that are based on
the patents and patent applications, relating to the Anti-CD55 Antibody Program,
including, but not limited to, those listed in Schedule "1".

               (ii)  Confidential  Information.  All  inventions,  developments,
improvements,  processes,  techniques,  methods, trade secrets, and confidential
information of any nature whatsoever  pertaining to the assets and properties of
Seller to be transferred  pursuant to this  Agreement  whether or not any of the
foregoing are patented or patentable.
<PAGE>
               (iii) Know-How and  Materials.  All of Seller's  books,  records,
correspondence,  plans,  drawings,  designs,  laboratory  note  books,  clinical
trials,  research  results,  cell lines,  files,  and other data with respect to
inventions,  laboratory and research results, formulae and inventions pertaining
to the  assets  and  properties  of Seller to be  transferred  pursuant  to this
Agreement, including, but not limited to, those listed in Schedule "2".

          (b)   Assets   and   Properties   Not  to  Be   Purchased   and  Sold.
Notwithstanding  anything to the contrary contained in this Agreement,  there is
excluded from the Purchased Assets the following:

               (i) All real property of Seller.

               (ii)  All  cash,   accounts   receivable,   debt,  and  corporate
documents.

     2. Liabilities of Seller.  Buyer is not assuming any liabilities of Seller.
Buyer shall not be deemed by anything contained herein to have assumed:

          (a) Any obligation or liability of Seller to Buyer or any other person
or entity which arises from, or the existence of which  constitutes,  any breach
of any covenant or agreement,  or a  misrepresentation  of any representation or
warranty, under this Agreement;

          (b) Any  obligation  or  liability  incurred by Seller on or after the
Closing Date;

          (c) Any obligation or liability of Seller  incurred in connection with
this Agreement or the transactions contemplated hereby; or

          (d) Any  obligation  or liability of Seller for any federal,  state or
local corporate income taxes,  property taxes,  payroll,  withholding and social
security taxes,  or other taxes of any kind or  description,  to which Seller is
subject.

     3. Consideration.

          (a) Common Stock of Parent.  In  consideration  of and in exchange for
the  Purchased  Assets,  Seller  shall be  entitled to receive an  aggregate  of
20,960,016 shares (the "Shares") of the common stock of Parent, par value $0.001
per share (the "Common Stock"), in accordance with subparagraph 3(b) below.

          (b)  Payment.  At the Closing,  Parent  shall  deliver to its transfer
agent an irrevocable  letter  instructing the transfer agent to issue the Shares
registered  in the name of Seller,  which Shares shall be delivered to Seller no
later than three (3)  business  days  following  its receipt of the  instruction
letter.

     4.  Seller's  Representations  and  Warranties.  Except as set forth on the
Disclosure Schedules delivered to Buyer at the Closing (the "Seller's Disclosure
Schedules"), Seller and Shareholders jointly and severally represent and warrant
and agree as follows:

                                       2
<PAGE>
          (a)  Corporate  Status  and  Authority.   Seller  is  a  company  duly
organized,  validly  existing and in good standing  under the laws of the Cayman
Islands,  has the requisite corporate power to own, operate and lease the assets
and  properties  being sold  hereunder and to carry on its business as it is now
being  conducted and is duly  qualified to do business in all  jurisdictions  in
which the nature of its business requires such qualification.  The execution and
delivery of this Agreement,  the consummation of the  transactions  contemplated
hereby and the  fulfillment of the terms hereof have been validly  authorized by
all  necessary  corporate  action  including,  but not limited  to,  shareholder
approval,  and this Agreement  constitutes  the valid and binding  obligation of
Seller enforceable in accordance with its terms.

          (b) Ownership of Assets and Properties. Seller has good and marketable
title  to,  is  the  exclusive  legal  and  equitable  owner  of,  and  ahs  the
unrestricted  power and right to sell,  assign, and deliver the Purchased Assets
to Buyer.  The  Purchased  Assets  are free and clear of all  liens,  mortgages,
pledges, security interests,  restrictions, prior assignments,  encumbrances and
claims of every kind and character.  Upon Closing, Buyer will acquire exclusive,
good,  and marketable  title to the Purchased  Assets and no  restrictions  will
exist on  Buyer's  right to  utilize,  exploit,  resell  or  license  any of the
Purchased Assets.

          (c) Condition of Assets and Properties.  All tangible Purchased Assets
are (i) in good operating condition and repair, ordinary wear and tear excepted;
and (ii) suitable and adequate for continued use in the manner in which they are
presently being used.

          (d) Compliance with Law and Other Regulations. Seller is in compliance
with all  requirements of federal,  state and local law, and all requirements of
all governmental bodies and agencies having jurisdiction over it, the conduct of
its business,  the use of its assets and properties and all premises occupied by
it. Without limiting the foregoing,  Seller has properly filed all reports, paid
all monies and obtained all licenses,  permits,  certificates and authorizations
needed or required for the conduct of its business and the use of its assets and
properties  and the premises  occupied by it in  connection  therewith and is in
compliance in all respects with all conditions,  restrictions  and provisions of
all of the  foregoing.  Seller  has not  received  any  notice,  not  heretofore
complied with,  from any federal,  state or local  authority or any insurance or
inspection  body that any of its assets,  properties,  facilities,  equipment or
business  procedures  or  practices  fails to comply  with any  applicable  law,
ordinance,  regulation,  building or zoning law,  or  requirement  of any public
authority or body.

          (e) Bulk  Sales.  Seller  has  complied  with all  legal  requirements
relating to the conveyance of the Purchased Assets, including but not limited to
requirements of any applicable  bulk sales laws or notices,  so that Buyer shall
have no responsibility to Seller's creditors.

          (f) Litigation.  There are no suits,  actions,  claims,  arbitrations,
administrative  or other proceedings or governmental  investigations  pending or
threatened  against or affecting Seller, its business or the Purchased Assets in
any  court or  before  or by any  federal,  state,  local or other  governmental
department  or agency,  and neither  Seller nor its  business  or the  Purchased
Assets are subject to or directly affected by any order, judgment, award, decree
or ruling of any court or  governmental  agency.  In addition to the  foregoing,
Seller  is not  contemplating  the  institution  of  any  suit,  action,  claim,
arbitration, administrative or other proceeding.

                                       3
<PAGE>
          (g) Agreement Not in Breach of Other Instruments Affecting Seller. The
execution and delivery of this Agreement,  the  consummation of the transactions
contemplated  hereby, and the fulfillment of the terms hereof,  will not violate
any  provision  of the  charter  documents  or by-laws of Seller,  nor will they
result in the breach of any term or provision  of, or result in the  termination
or  modification  of, or constitute a default under,  or conflict with, or cause
the  acceleration  of any  obligation  of Seller  under,  or permit any party to
modify or terminate, any loan agreement, note, debenture,  indenture,  mortgage,
deed of trust, lease, contract, agreement or other obligation of any description
to which  Seller is a party or by which it is bound,  or any  judgment,  decree,
order, or award of any court, governmental body, or arbitrator or any applicable
law, rule or regulation.

          (h)  Statements  and Other  Documents  Not  Misleading.  Neither  this
Agreement,  including all schedules and exhibits hereto,  nor any other document
or  instrument  furnished  or delivered  by Seller or  Shareholders  to Buyer in
connection  with  the  transactions  contemplated  hereby,  contain  any  untrue
statement  of  material  fact or omit to state a material  fact  required  to be
stated  in order to make  such  statement,  document  or  other  instrument  not
misleading.  In addition to the foregoing,  neither Seller nor Shareholders have
failed to inform Buyer as to any material  fact  relating to Seller's  business,
assets, properties, prospects or affairs.

          (i) Investment Representations, Warranties and Covenants by Seller.

               (i) Seller has been advised and acknowledges that: (A) the Shares
have not been, and when issued,  will not be registered under the Securities Act
of 1933, as amended (the "Securities  Act"), the securities laws of any state of
the  United  States or the  securities  laws of any other  jurisdiction;  (B) in
issuing and selling the Shares to Seller pursuant hereto,  Buyer is relying upon
the "safe  harbor"  provided by  Regulation  S and/or on Section  4(2) under the
Securities  Act; (C) it is a condition to the  availability  of the Regulation S
"safe  harbor" that the Shares not be offered or sold in the United States or to
a U.S. person until the expiration of a period of one year following the Closing
Date.  As used in this  Agreement,  the term "U.S.  person" and "United  States"
shall have the same  definitions  as those  provided in  Regulation  S under the
Securities Act; and (D) notwithstanding  the foregoing,  prior to the expiration
of one year  after the  Closing  (the  "Restricted  Period"),  the Shares may be
offered and sold by the holder thereof only if either:  (I) if the offer or sale
is within the United  States or to or for the account of a U.S.  person (as such
terms are defined in Regulation S), the securities are offered and sold pursuant
to an  effective  registration  statement  or  pursuant  to Rule 144  under  the
Securities Act or pursuant to an exemption from the registration requirements of
the Securities  Act; or (II) the offer and sale is outside the United States and
to other than a U.S. person.

               (ii)  Seller  agrees  that with  respect to the Shares  until the
expiration  of  the   Restricted   Period:   (A)  Seller,   its  agents  or  its
representatives  have not and will not solicit  offers to buy, offer for sale or
sell any of the Shares or any beneficial  interest  therein in the United States
or to or for the account of a U.S.  person  during the  Restricted  Period;  (B)
notwithstanding the foregoing, prior to the expiration of the Restricted Period,
the Shares may be offered and sold by the holder thereof only if either:  (I) if
the offer or sale is within the United States or to or for the account of a U.S.
person,   the   securities  are  offered  and  sold  pursuant  to  an  effective
registration statement or pursuant to Rule 144 under the Securities Act or

                                       4
<PAGE>
pursuant to an exemption from the  registration  requirements  of the Securities
Act; or (II) the offer and sale is outside the United States and to other than a
U.S.  person;  and (III)  Seller shall not engage in hedging  transactions  with
regard to the Shares unless in compliance with the Securities Act.

               (iii)  The  restrictions   herein  are  binding  upon  subsequent
transferees  of the  Shares  except for  transferees  pursuant  to an  effective
registration  statement.  Seller agrees that after the  Restricted  Period,  the
Shares may be offered or sold within the United  States or to or for the account
of a U.S. person only pursuant to applicable securities laws.

               (iv) Seller has not  engaged,  nor is it aware that any party has
engaged,  and Seller will not engage or cause any third party to engage,  in any
directed selling efforts (as such term is defined in Regulation S) in the United
States with respect to the Shares.

               (v)  Seller:  (A) is  domiciled  and has its  principal  place of
business outside the United States; (B) certifies it is not a U.S. person and is
not acquiring the Shares for the account or benefit of any U.S. person;  (C) was
not  formed  by a U.S.  person  principally  for the  purpose  of  investing  in
securities not registered  under the Securities Act.; and (D) at the time of the
Closing  Date,  Seller or  persons  acting  on  Seller's  behalf  in  connection
therewith  will be located  outside  the  United  States.  (vi)  Seller is not a
"distributor"  (as  defined in  Regulation  S) or a "dealer"  (as defined in the
Securities Act).

               (vii) Seller acknowledges that Buyer shall make a notation in its
stock books  regarding  the  restrictions  on transfer  described  herein  shall
transfer  such  shares on the books of the Buyer only to the  extent  consistent
therewith.

               (viii) Seller  understands and agrees that each  certificate held
by Seller  representing the Shares, or any other securities issued in respect of
the Shares  upon any stock  split,  stock  dividend,  recapitalization,  merger,
consolidation or similar event,  shall bear the following legend (in addition to
any legend required under applicable securities laws):

            THE SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER
            THE  SECURITIES  ACT OF 1933,  AS AMENDED  (THE  "SECURITIES
            ACT"), AND MAY NOT BE SOLD, TRANSFERRED,  ASSIGNED,  PLEDGED
            OR HYPOTHECATED  EXCEPT IN ACCORDANCE WITH THE PROVISIONS OF
            REGULATION S PROMULGATED  UNDER THE SECURITIES ACT, PURSUANT
            TO  REGISTRATION  UNDER THE SECURITIES ACT OR PURSUANT TO AN
            AVAILABLE EXEMPTION FROM REGISTRATION.  HEDGING TRANSACTIONS
            INVOLVING THE SHARES REPRESENTED HEREBY MAY NOT BE CONDUCTED
            UNLESS  IN  COMPLIANCE   WITH  THE   SECURITIES   ACT.  THIS
            CERTIFICATE  MUST  BE  SURRENDERED  TO  THE  COMPANY  OR ITS

                                       5
<PAGE>
            TRANSFER AGENT AS A CONDITION PRECEDENT TO THE SALE, PLEDGE,
            HYPOTHECATION  OR ANY OTHER  TRANSFER OF ANY INTEREST IN ANY
            OF THE SHARES REPRESENTED BY THIS CERTIFICATE.

               (ix) Seller hereby  represents that Seller is satisfied as to the
full  observance  of the laws of the Cayman  Islands in  connection  with offer,
sale, and purchase of the Shares  including (A) the legal  requirements  for the
purchase of Shares,  (B) any foreign  exchange  restrictions  applicable to such
purchase,  (C) any  governmental  or other consents that may need to be obtained
and (D) the income tax and other tax consequences,  if any, that may be relevant
to the purchase,  holding,  redemption, sale or transfer of the Shares. Seller's
purchase and payment for, and continued beneficial ownership of, the Shares will
not violate any applicable securities or other laws of the Cayman Islands.

     5. Further Representations and Warranties of Shareholders.  To induce Buyer
to enter into this Agreement and for the benefit of Buyer,  Shareholders further
represent and warrant as follows:

          (a) Ownership of Capital Stock of Seller.  Shareholders own 179 shares
of Common  Stock of  Seller,  constituting  all of the  issued  and  outstanding
capital stock of Seller.  Shareholders  have good,  marketable and  unencumbered
title to such stock. No transfer of record ownership of, or beneficial  interest
in, any of such stock will be made between the date hereof and the Closing.

          (b)  Consent to  Transaction.  Shareholders,  constituting  all of the
shareholders of Seller,  hereby consent to the transactions herein provided for,
and agree that this consent in writing shall be deemed to be the action required
by the charter  documents and by-laws of Seller and the  applicable  laws of the
Cayman Islands.  Each  Shareholder  agrees to vote all of its shares of stock of
Seller in favor of approving  any and all other action  necessary to be taken by
Seller in order to comply fully with this Agreement,  at any and all meetings of
Seller held for any such purpose.

          (c) Power of Shareholders to Execute Agreement. Shareholders have full
power and  authority to execute,  deliver and perform this  Agreement,  and this
Agreement is the legal and binding obligation of Shareholders and is enforceable
against them in accordance with its terms.

          (d)   Agreement   Not  in  Breach  of  Other   Instruments   Affecting
Shareholders.  The execution and delivery of this Agreement, the consummation of
the transactions hereby  contemplated,  and the fulfillment of the terms hereof,
will not  result in the  breach of any term or  provision  of, or  constitute  a
default  under,  or conflict with, or cause the  acceleration  of any obligation
under,  any  agreement  or other  instrument  of any  description  to which  any
Shareholder is a party or by which any is bound, or any judgment, decree, order,
or award of any court,  governmental body, or arbitrator, or any applicable law,
rule or regulation.

                                       6
<PAGE>
     6.  Buyer's   Representations   and   Warranties.   To  induce  Seller  and
Shareholders  to enter into this  Agreement,  Buyer  represents  and warrants as
follows:

          (a) Corporate Status and Authority.  Buyer is, and at the Closing will
be, a corporation  duly organized,  validly  existing and in good standing under
the laws of the State of Nevada.  The execution  and delivery of this  Agreement
and the consummation of the transactions  contemplated  hereby have been validly
authorized by all appropriate corporate action.

          (b)  Agreement Not in Breach of Other  Instruments.  The execution and
delivery of this Agreement,  the consummation of the  transactions  contemplated
hereby, and the fulfillment of the terms hereof,  will not violate any provision
of the articles of incorporation or by-laws of Buyer nor will they result in the
breach of any term or provision of, or constitute a default  under,  or conflict
with, or cause the  acceleration  of any obligation  under,  any loan agreement,
note, debenture,  indenture, mortgage, deed of trust, lease, contract, agreement
or other  obligation  of any  description  to which Buyer is a party or by which
either  is  bound,  or any  judgment,  decree,  order,  or award  of any  court,
governmental body or arbitrator, or any applicable law, rule or regulation.

     7. Continuation and Survival of Representations and Warranties. Each of the
representations  and warranties  contained in this  Agreement  shall be true and
correct on and as of the Closing Date. All such  representations  and warranties
shall  survive  the  consummation  of  the  transactions  contemplated  by  this
Agreement  irrespective of any  investigations or inquiries made by any party or
any knowledge which any party may now possess or which may hereafter come to any
party's  attention,  and  each  party  shall  be  entitled  to  rely  upon  such
representations and warranties irrespective of any investigations,  inquiries or
knowledge.

     8.  Closing.  The  Closing  under  this  Agreement  shall take place at the
offices of Greenberg  Traurig,  LLP, 3161 Michelson Drive,  Suite 1000,  Irvine,
California on or before March 31, 2010, or at such other date, time and place as
may be agreed upon by Seller and Buyer,  which date is sometimes  herein  called
the "Closing Date".

          (a) Deliveries by Seller.

               (i) At the  Closing,  Seller  shall  deliver to Buyer such deeds,
bills of sale,  instruments of assignment and other instruments and documents as
may be necessary to convey to Buyer title to the Purchased Assets.

               (ii) On or prior to the Closing,  Seller shall deliver,  or cause
the delivery of, the Purchased Assets to Buyer,  including,  without limitation,
all copies of the patents and patent  applications  set forth in Section 1(a)(i)
above and related  documents  and records and all of the tangible  materials set
forth in Section 1(a)(ii) above.

All assignments,  consents, certificates and other documents delivered by Seller
shall be in form reasonably satisfactory to counsel for Buyer.

                                       7
<PAGE>
          (b) Deliveries by Buyer.  At the Closing,  Parent shall deliver a copy
of the  executed  irrevocable  letter  instructing  Parent's  transfer  agent to
deliver the Shares to Seller and  evidence of its  delivery of the letter to the
transfer agent.

All  certificates  and  other  documents  delivered  by  Buyer  shall be in form
reasonably satisfactory to counsel for Seller.

     9. Further Assurances. Seller, Shareholders, Parent and Buyer shall execute
and deliver  all such other  instruments  and take all such other  action as any
party may reasonably request from time to time, before or after the Closing,  in
order to  effectuate  the  transactions  provided for herein.  The parties shall
cooperate with each other and with their  respective  counsel and accountants in
connection with any steps to be taken as a part of their respective  obligations
under this Agreement.

     10. Indemnification.

          (a)  Indemnity  Against  Losses  from  Untruth of  Representations  or
Warranties or Breach of  Agreements or Covenants.  In the event that at any time
hereafter  it shall  appear  that any  representation  or  warranty of Seller or
Shareholders  contained or referred to in any paragraph of this  Agreement or in
any certificate,  schedule,  exhibit or document  delivered  pursuant hereto was
incorrect  or untrue,  or that Seller or  Shareholders  breached any covenant or
agreement  contained  in this  Agreement,  Seller and  Shareholders  jointly and
severally shall pay Buyer the amount of the loss,  expense or damage suffered or
incurred by Buyer,  which would not have been  suffered or incurred if the facts
set forth in those  representations  or  warranties  had been  correct  or those
covenants and agreements had not been breached.

          (b) Indemnity  Against  Suits and Claims.  Without in any way limiting
any of the rights of Buyer, Seller and Shareholders hereby jointly and severally
indemnify and hold harmless Buyer from all liabilities,  suits, claims, demands,
damages,   fees,  costs  and  expenses  (including   reasonable  attorney's  and
accountant's  fees) arising out of the  incorrectness of any  representation  or
warranty or the breach of any  agreement  or covenant of Seller or  Shareholders
under this  Agreement.  Upon written  demand by Buyer,  Seller and  Shareholders
shall defend  against any liability,  suits,  claims and demands which may arise
from the incorrectness of those  representations  or warranties or the breach of
those covenants and  agreements.  Seller and  Shareholders  shall retain counsel
reasonably  satisfactory  to Buyer and conduct any defense  diligently and shall
keep Buyer advised of the status of such defense. If Seller and Shareholders are
called upon to defend,  Buyer shall be entitled to participate,  through counsel
of their own choice, in any such defense, at Buyer's expense.

     11. Brokers and Finders. Each of the parties hereto represents and warrants
to the  others  that it has not  employed  or  retained  any broker or finder in
connection with the  transactions  contemplated by this Agreement nor has it had
any  dealings  with  any  person  which  may  entitle  that  person  to a fee or
commission  from any other party  hereto.  Each of the parties  indemnifies  and
holds the  others  harmless  from and  against  any  claim,  demand  or  damages
whatsoever by virtue of any  arrangement or commitment made by it with or to any
person that may  entitle  such  person to any fee or  commission  from the other
parties to this Agreement.

                                       8
<PAGE>
     12.  Shareholders'  Guarantees.  Shareholders  hereby jointly and severally
unconditionally  guarantee to Buyer and become  sureties for the  performance of
and  compliance  with all of  Seller's  agreements,  covenants  and  obligations
hereunder and the truth and correctness of all of Seller's  representations  and
warranties  contained  herein.  Any claim or right of Buyer for the  failure  to
perform or comply  with any of Seller's  agreements,  covenants  or  obligations
hereunder or for the untruth or incorrectness of any of its  representations  or
warranties  contained  herein may be directly  enforced  against any Shareholder
without  any notice of any kind and  without  first  making  any demand  upon or
pursuing  any  remedy  against  Seller.  Without  notice  to or  consent  of any
Shareholder,  Buyer  may  modify or change  the terms of this  Agreement  or any
obligation  of  Seller,  and may grant any  extension,  renewal  or  indulgence,
release, compromise or settlement with respect thereto and none of the foregoing
shall in any way affect Shareholders' liability hereunder.

     13. General Provisions.

          (a) Binding Nature of Agreement;  Assignment.  This Agreement shall be
binding upon and inure to the benefit of the parties hereto and their respective
successors  and assigns,  except that no party may assign or transfer its or his
rights or obligations  under this Agreement without the prior written consent of
the other parties hereto.

          (b) Entire Agreement. This Agreement contains the entire agreement and
understanding  among the  parties  hereto  with  respect to the  subject  matter
hereof, and supersedes all prior and contemporaneous agreements, understandings,
inducements and conditions,  express or implied,  oral or written, of any nature
whatsoever  with respect to the subject matter hereof.  The express terms hereof
control  and  supersede  any  course of  performance  and/or  usage of the trade
inconsistent with any of the terms hereof. This Agreement may not be modified or
amended other than by an agreement in writing.

          (c) Governing  Law. This  Agreement and all questions  relating to its
validity, interpretation,  performance and enforcement, shall be governed by and
construed,  interpreted and enforced in accordance with the laws of the State of
Nevada, notwithstanding any conflict-of-law provisions to the contrary.

          (d)  Schedules and  Exhibits.  All Schedules and Exhibits  referred to
herein are hereby  incorporated  by  reference  into,  and made a Part of,  this
Agreement.

          (e) Indulgences, Not Waivers. Neither the failure nor any delay on the
part of a party to exercise any right,  remedy,  power or  privilege  under this
Agreement  shall  operate as a waiver  thereof,  nor shall any single or partial
exercise of any right,  remedy, power or privilege preclude any other or further
exercise of the same or of any other  right,  remedy,  power or  privilege,  nor
shall any waiver of any right,  remedy,  power or privilege  with respect to any
occurrence  be construed as a waiver of such right,  remedy,  power or privilege
with respect to any other occurrence.  No waiver shall be effective unless it is
in writing and is signed by the party asserted to have granted such waiver.

          (f) Costs and  Expenses.  Each party  hereto shall bear its or his own
costs  and  expenses  (including  the  fees and  disbursements  of  counsel  and

                                       9
<PAGE>
accountants)  incurred in connection with the negotiation and preparation of and
the closing under this Agreement, and all matters incident thereto.

          (g) Titles Not to Affect Interpretation.  The titles of paragraphs and
subparagraphs  contained in this  Agreement are for  convenience  only, and they
neither  form  a  part  of  this  Agreement  nor  are  they  to be  used  in the
construction or interpretation hereof.

          (h) Execution in  Counterparts.  This Agreement may be executed in any
number of  counterparts,  each of which  shall be deemed  to be an  original  as
against  any party  whose  signature  appears  thereon,  and all of which  shall
together  constitute one and the same  instrument.  This Agreement  shall become
binding when one or more  counterparts  hereof,  individually or taken together,
shall  bear  the  signatures  of all  of the  parties  reflected  hereon  as the
signatories.  Any  photographic  or  xerox  copy of  this  Agreement,  with  all
signatures  reproduced  on one  or  more  sets  of  signature  pages,  shall  be
considered  for all  purposes  as of it were an  executed  counter  part of this
Agreement.

          (i)  Provisions  Separable.  The  provisions  of  this  Agreement  are
independent and separable from each other, and no provision shall be affected or
rendered  invalid or unenforceable by virtue of the fact that for any reason and
other or others of them may be invalid or unenforceable in whole or in part.

                    [Remainder of page intentionally blank.]

                                       10
<PAGE>
     IN WITNESS  WHEREOF,  each of the parties has caused this  Agreement  to be
executed on its behalf by their  respective  officers  thereunto duly authorized
all as of the date first written above.

                                  "PARENT"

                                  FREIGHT MANAGEMENT CORP.

                                  By: /s/ Ibrahim Abotaleb
                                     -------------------------------------------
                                  Name: Ibrahim Abotaleb
                                       -----------------------------------------
                                  Title: President and CEO
                                        ----------------------------------------

                                  "BUYER"

                                  GENESIS BIOPHARMA, INC.

                                  By: /s/ Robert Brooke
                                     -------------------------------------------
                                  Name: Robert Brooke
                                       -----------------------------------------
                                  Title: President and CEO
                                        ----------------------------------------

                                  "SELLER"

                                  HAMILTON ATLANTIC

                                  By: /s/ Amy Wang
                                     -------------------------------------------
                                  Name: Amy Wang
                                       -----------------------------------------
                                  Title: Director
                                        ----------------------------------------

                                  "SHAREHOLDERS"

                                  PRO-FUND ADMINISTRATION LTD.

                                  By: /s/ Graham May
                                     -------------------------------------------
                                  Name: Graham May
                                       -----------------------------------------
                                  Title: Secretary
                                        ----------------------------------------

                                  BRISTOL INVESTMENT FUND, LTD.

                                  By: /s/ Paul Kessler
                                     -------------------------------------------
                                  Name: Paul Kessler
                                       -----------------------------------------
                                  Title: Director
                                        ----------------------------------------

                                       11
<PAGE>
     IN WITNESS  WHEREOF,  each of the parties has caused this  Agreement  to be
executed on its behalf by their  respective  officers  thereunto duly authorized
all as of the date first written above.

                                  "SHAREHOLDERS"

                                  BATAVIA HOLDINGS LIMITED

                                  By: /s/ Janny Onggara
                                     -------------------------------------------
                                  Name: Janny Onggara
                                       -----------------------------------------
                                  Title: Director
                                        ----------------------------------------

                                  0796625 B.C. LTD.

                                  By: /s/ Shirazali Jumani
                                     -------------------------------------------
                                  Name: Shirazali Jumani
                                       -----------------------------------------
                                  Title: President and Director
                                        ----------------------------------------

                                       12
<PAGE>
                                  SCHEDULE "1"

                         PATENTS AND PATENT APPLICATIONS

<TABLE>
<CAPTION>
                                    Applicant                 Priority Date                VSL Reference /
     Title                        (VSL/Viragen)                and Number                      Comment
     -----                        -------------                ----------                      -------
<S>                           <C>                          <C>                               <C>
Interferon-alpha 1 for          Hamilton Atlantic          GB 0812442.2                         VG108
use as an                                                  Priority date 7th July 2008
immunological adjuvant

Interferon-alpha 10             Hamilton Atlantic          GB 0812046.1                         VG107
for use as an                                              Priority date 1st July 2008
immunological
adjuvant

Use of Interferon alpha        Viragen Inc. and            GB 0619816.2                         VG106
14 in the Treatment of         Viragen (Scotland) Ltd      6th October 2006                     Note: This
Cancer                                                                                          application
                                                                                                terminated on 7
                                                                                                December 2007

Use of Interferon alpha        Viragen Inc. and            PCT/GB2007/003814                    VG106
14 in the Treatment of         Viragen (Scotland) Ltd      filed 8th October 2007
Cancer

Interferon alpha-14 for        Viragen Inc.                GB 0619814.7                         VG106
use as an immunological                                    6th October 2006
adjuvant

Composition and                Viragen Inc.                GB 0507963.7                         VG106
Method for treating                                        20th April 2005                      N.B. This
disease                                                                                         application
                                                                                                terminated on 21
                                                                                                April 2006

Composition and                Viragen Inc.                GB 0522732.7                         VG106
Method for treating                                        7th November 2005                    N.B. This
disease                                                                                         application
                                                                                                terminated on 8
                                                                                                November 2006

Composition and                Viragen Inc.                US  60/741,734                       VG106
Method for treating                                        2nd December 2005
disease

Composition and                Viragen Inc.                PCT/GB2006/001432                    VG106
method for treating                                        Filed 20th April 2006                Filed in EU, AU,
viral infection                                            (WO 2006/11745)                      IN,CH National
                                                                                                phase
</TABLE>
<PAGE>
<TABLE>
<CAPTION>
                                    Applicant                 Priority Date                VSL Reference /
     Title                        (VSL/Viragen)                and Number                      Comment
     -----                        -------------                ----------                      -------
<S>                           <C>                          <C>                               <C>
Multisubtype interferon        Viragen Inc.                GB 0619815.4
alpha for use as an                                        6th October 2006
immunological adjuvant
</TABLE>

<PAGE>
                                  SCHEDULE "2"

                             KNOW-HOW AND MATERIALS

A. The following books and records:

BOX NUMBER                              CONTENTS
----------                              --------

334314711                   Anti CD55 Patent App - Countries A-G
                            CD55 Correspondence 2004-2005
                            CD55 Correspondence 2002-2003
                            Anti CD55 Patent App - Countries H-Z
                            CD55 Binding

334314712                   CRT License Correspondence
                            CRCT Contract Copies

334314713                   IFN Alpha 14
                            IFN Alpha 14
                            IFN Alpha 14 Cancer
                            IFN Alpha 14 Viral 1
                            IFN Alpha 14 Viral 2
                            IFN Alpha 14 as Adjuvant
                            IFN  Alpha  1  as  an   Immunological
                            Adjuvant  VG108  IFN  Alpha  10 as an
                            Immunological Adjuvant VG107

334314715                   VG106 Freedom to Op Search Aug/Sep 07
                            Patent  Application  WO  01/25438  A2
                            Patent  Application  WO  83/04053  US
                            Patent US6610830 B1 Patent
                            Application WO  02/36627  A2 Patent
                            Application WO 2006/079121 A2 Patent
                            Application WO 2007/000769 A2 Patent
                            Application WO 2004/031352 A2 Patent
                            Application WO 2004/022593 A2 Patent
                            Application WO 2006/020580 A2 Patent
                            Application WO 2004/046365 A2

334314717                   Patent Info IFN A & B

334314718                   Specific Binding Members

334314721                   Algonomics NV
                            Lonza Biologics
                            Southern Research Institute

334314731                   Antipoliferation  Patent  Book 1
                            General & Daudi Cell Line
                            WM-266-4 Cell Line
                            Malme - 3M Cell Line
                            General & Daudi Cell Line
                            General & Daudi Cell Line Book 3
<PAGE>
                            Skemel 5 Cell Line
                            Skemel 28 Cell Line
                            Skemel 2 Cell Line
                            Mewo Cell Line
                            HT-144 Cell Line
                            WM35 Cell Line
                            G-361 Cell Line
                            IFN Alpha Subtypes Book 8
                            General Purification Book 1
                            Cell Culture Work Book 1
                            Chimeric Antibodies Analysis Book 2
                            General Assay Book
                            Chimeric Antibody Analysis 1
                            CD55 Book 1

334314732                   CD55 Book 2
                            MDR Project Book 1
                            A-375 Cell Line
                            791T/36 Research Book 2
                            General Molecular/Cell Culture Work Book 1
                            791T36 Book 8
                            791T36 Research Book 10
                            791T36 Research Book 12
                            PLD79
                            791T Research Book 14
                            General Cell Culture Book 2
                            VG106 Book 1
                            VG107/VG108 Book 1

334314736                   105AD7 (Onyvax 105)
                            EN-CD55
                            Complement
                            Panorex (Edrecolomab)
                            Rituximab

334314737                   Monoclonal Antibody
                            Cancer Mabs
                            Cancer

334314746                   Lonza CD55/R24
                            IFN Subtypes

334314747                   VG102
                            VG106

334314748     Lab Books     Dev100 - Interferon Work 3
                            Dev101 - INF Comparison Book 7 C Haslam
                            Dev106 - 791T36 6
                            Dev108 - General Cell Culture 2
                            Dev124 - 791T Research 7 L Davidson
                            Dev125 - Interferon Comparison 8
                            Dev126 - Expression & Production of Human Antibodies

334314749     Lab Books     Dev 75 - Recombinant Interferon 2
<PAGE>
                            Dev 76 - Interferon 1
                            Dev77 - CD55 Antiody & Derivatives 1
                            Dev78 - 791T36 3
                            Dev79 - Interferon Comparison 3
                            Dev83 - Interferon Comparison 6
                            Dev86 - Interferon Work 2
                            Dev89 - General Cell Culture 1
                            Dev90 - Recombinant Interferon 3
                            Dev93 - Interferon Comparison 4
                            Dev94 - CD55
                            Dev95 - CD55 2
                            Dev96 - Bioassay Cell Lines 1
                            Dev96a - Interferon Work 1
                            Dev97 - 791T36 5

334314750     Lab Books     Dev48 - Antibody Work
                            Dev49 - Dev of IFN Elisa Based Assay Bk 1
                            Dev50 - Molecular Science Bk 2
                            Dev54 - Mab Purification Bk 6
                            Dev55 - 791T36 Bk 1
                            Dev61 - Interferon Research Bk 1
                            Dev62 - Molecular Science Bk 4
                            Dev63 - 791T36 Bk 2
                            Dev66 - Recombinant Interferon Bk 1
                            Dev67 - Interferon Research Bk 2
                            Dev72 - Interferon Comparison Bk 5

334314751     Lab Books     Dev171 - R24 & 791T36 Antibody 2
                            Dev173 - 791T36 Research 9 L Davidson
                            Dev186 - Interferon 7 P Barnard

334314752     Lab Books     Dev202 - IFN Alpha Subtypes Purification 2 J Smith
                            Dev209 - IFN Alpha Subtypes 3
                            Dev212 - IFN Alpha Subtypes 4
                            Dev216 - Real Time PCR Book 1 C Haslam
                            Dev219 - IFN Alpha Subtypes 5 J Smith
                            Dev223 - IFN Alpha Subtypes 6 J Smith
                            Dev228 - 791T36 13 L Davidson
                            Dev231 - IFN Alpha Subtypes 7 J Smith

334314753     Lab Books     Dev134 - IFN Alpha 14 5 P Barnard
                            Dev141 - Alpha 14 1
                            Dev146 - Anti CD59 - Antibodes 1
                            Dev153 - Interferon 6 P Barnard
                            Dev160 - Alpha 14 2 N McLean
                            Dev161 - R24 & 791T36 Antibody Expression 1 C Haslam
                            Dev167 - IFN & Subtypes Purification 1 J Smith

334314755                   IFN 14/N72D
                            CD55 General Info

334314764                   Spur & CD55 Applications & Claims

334314765                   Spur Grant Claims
<PAGE>
334314787                   VG106 Anti-viral Search Report
                            Alpha 14 - Folders 1-3
                            VG106 Intellectual Property File

334314792                   CD55
                            CRCT
                            General Antibody Gene Stuff CD55
                            E Coli Recombinants
                            CD46
                            Peptech
                            Dyax
                            A6 Studies Archive

334314799                   VG106
                            VG106 Aptuit
                            VG106 Xenograft
                            VG106 / Multiferon Adjuvants
                            VG107/8
                            IFN-X Subtype Exploitation
                            VG102 IP
                            VG102 General
                            VG102 Immunogenicity
                            CD55 Literature

B.   The following cell lines currently  preserved in liquid nitrogen and stored
     in standard freezers:

(i)  Chinese Hamster Ovary (CHO) cell line(s)  producing the biological  protein
     referred to as VG102 in its three variant forms;

(ii) Chinese  Hamster  Ovary (CHO) cell line  producing the  biological  protein
     referred to as VG106;

(iii)Chinese  Hamster  Ovary (CHO) cell line  producing the  biological  protein
     referred to as VG107; and

(iv) Chinese  Hamster  Ovary (CHO) cell line  producing the  biological  protein
     referred to as VG108.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}]]